- Home
- ARWR vs MLCO Comparison
ARWR vs MLCO Comparison
Compare ARWR & MLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARWR
- MLCO
- Stock Information
- Founded
- ARWR 2003
- MLCO 2004
- Country
- ARWR United States
- MLCO Hong Kong
- Employees
- ARWR N/A
- MLCO N/A
- Industry
- ARWR Biotechnology: Pharmaceutical Preparations
- MLCO Hotels/Resorts
- Sector
- ARWR Health Care
- MLCO Consumer Discretionary
- Exchange
- ARWR Nasdaq
- MLCO Nasdaq
- Market Cap
- ARWR 1.7B
- MLCO 2.0B
- IPO Year
- ARWR 1993
- MLCO 2006
- Fundamental
- Price
- ARWR $11.24
- MLCO $4.84
- Analyst Decision
- ARWR Buy
- MLCO Buy
- Analyst Count
- ARWR 11
- MLCO 6
- Target Price
- ARWR $41.44
- MLCO $7.70
- AVG Volume (30 Days)
- ARWR 2.3M
- MLCO 5.4M
- Earning Date
- ARWR 05-08-2025
- MLCO 04-29-2025
- Dividend Yield
- ARWR N/A
- MLCO N/A
- EPS Growth
- ARWR N/A
- MLCO N/A
- EPS
- ARWR N/A
- MLCO 0.10
- Revenue
- ARWR $2,500,000.00
- MLCO $4,638,213,000.00
- Revenue This Year
- ARWR $4,380.43
- MLCO $7.74
- Revenue Next Year
- ARWR $64.24
- MLCO $5.56
- P/E Ratio
- ARWR N/A
- MLCO $48.03
- Revenue Growth
- ARWR N/A
- MLCO 22.86
- 52 Week Low
- ARWR $9.57
- MLCO $4.55
- 52 Week High
- ARWR $30.41
- MLCO $8.90
- Technical
- Relative Strength Index (RSI)
- ARWR 38.40
- MLCO 41.13
- Support Level
- ARWR $9.64
- MLCO $4.68
- Resistance Level
- ARWR $12.93
- MLCO $5.03
- Average True Range (ATR)
- ARWR 1.18
- MLCO 0.31
- MACD
- ARWR 0.18
- MLCO -0.01
- Stochastic Oscillator
- ARWR 43.21
- MLCO 33.33
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
About MLCO Melco Resorts & Entertainment Limited
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao with the rest largely from the Philippines as of 2019.